Quick Answer
Aardvark Therapeutics, Inc. reported Research And Development Expense of $48.94 million for the year ending 2025.
- Aardvark Therapeutics, Inc. showed an increase of +181.8% in Research And Development Expense from 2024 to 2025.
- This data is from Aardvark Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $1.21 million | Q2 2024: $4.03 million | Q3 2024: $4.07 million | Q1 2025: $7.76 million | Q2 2025: $13.15 million | Q3 2025: $13.74 million.
- Historical annual values: Fiscal year 2025: $48.94 million | Fiscal year 2024: $17.36 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: